A Clinical Study to Assess the Safety and Effectiveness of Plant-based Biotin and Plant Based Biotin With Silica in Healthy Human Subjects With Complaints of Hair Fall, Thin, Dry, & Brittle Hair, and Dry Skin

Dry Skin Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Safety, and Efficacy Study of Plant Based Biotin and Plant Based Biotin With Silica in Healthy Adult Human Subjects With Complaints of Hair Fall Thin, Dry, & Brittle Hair, and Dry Skin

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05972512
• Other study ID #: NB230019-OI
• Status: Recruiting
• Phase: N/A
• Start date: October 24, 2023
• Est. completion date: February 29, 2024

Study information

• Verified date: November 2023
• Source: NovoBliss Research Pvt Ltd
• Contact: Maheshvari N Patel
• Phone: 9909013236
• Email: maheshvari[@]novobliss.in
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, double-blind, three-arm, placebo-controlled, safety, and efficacy study of plant-based Biotin and plant-based Biotin with Silica in healthy adult human subjects with complaints of hair fall, thin, dry, and brittle hair, and dry skin.

A sufficient number (maximum of 105 (35 subject/test treatment)) of female/male adult subjects will be recruited/enrolled to ensure a total of 96 subjects (32 subjects/test treatment) complete the study.

Description:

The potential subjects will be screened as per the inclusion & exclusion criteria only after obtaining written informed consent from the subjects. Total study visits will be 8 during this study.

Visit 01 (Within 30 Days): Screening procedure, Informed consent obtain process, baseline evaluations, blood collection, tattoo on scalp, hair growth rate measurement Visit 02 (Day 01): Enrolments, hair growth rate measurement, other evaluations, product distribution, diary distribution, AE reporting (if any.

Visit 03 (Day 27 +2 Days): Treatment period, evaluations, tattoo, hair growth rate measurement, diary card review, AE reporting (if any).

Visit 04 (3 Days from Visit 03): Treatment period, evaluations, diary card review, AE Reporting (if any).

Visit 05 (Day 57 + 2Days): Treatment period, evaluations, tattoo, hair growth rate measurement, diary card review, AE Reporting (if any).

Visit 06 (3 Days from Visit 05): Treatment period, evaluations, diary card review, AE Reporting (if any).

Visit 07 (Day 87 +2 Days): Treatment period, evaluations, tattoo, hair growth rate measurement, diary card review, AE Reporting (if any).

Visit 08 (3 days from Visit 08): Evaluations, dairy card collection, AE reporting, test treatments accountability, End of Study process.

done on Day 04 before Day 01, Day 01 and after test treatment usage will be done on Day 27, Day 30, Day 57, Day 60, Day 87, Day 90 as listed-below.

• 60-S Hair Combing Method: Hair Fall.

• CASALite Nova (Phototrichogram): Hair Density, Thickness, Hair Growth Rate, Scalp Condition.

• PGA Score: Signs of brittle nails, surface roughness, raggedness and peeling.

• Visioscan®VC 20plus (C+K Instrument): Crow's feet area wrinkles, fine lines, skin texture - roughness, dryness, wrinkles, smoothness (Right cheek).

• MoitureMeterEPiD: Skin hydration (Right cheek).

• Hair Pull Test: Hair strength.

• Pluck Test: A:T ratio (Hair Growth Cycle)

• Cutometer: Skin elasticity (Right cheek).

• PGA Griffith Scale: Skin dryness, redness, fine wrinkling/lines, coarse wrinkling/lines, laxity, roughness and sallowness

• Tewameter® TM 300: Skin barrier function (Right Cheek)

• General Appearance of Hair: Hair shininess, hair reflection, hair plasticity, hair fizziness, hair volume, hair density Digital photographs: Facial photographs before test treatment consumption and after test treatment consumption

• Blood parameters: CBC, total Serum Cholesterol, Triglyceride, Random Glucose, LDL, HDL [Note: blood collection will be performed on Day 01 And Day 90]

• Blood parameter: HBsAg (Hepatitis B surface antigen) - Screening only

• Subjective product perception assessment regarding the test treatment's effect on skin elasticity, suppleness, skin color, fragrance, taste, skin hydration, skin tone, firmness, appearance, hair and nails, strongness and shine.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 105
• Est. completion date: February 29, 2024
• Est. primary completion date: December 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Age: 20 to 60 years (both inclusive) at the time of consent

2. Sex: Healthy males and non-pregnant/non-lactating females.

3. Subject have complaints of hair fall, thin, dry and brittle hair, and dry skin.

4. Females of childbearing potential must have a reported negative pregnancy test.

5. Subject are generally in good health.

6. Subject must have negative Hepatitis B Surface Antigen Test at baseline.

7. Subject with self-proclaimed nonpathological thin, dry and brittle hair.

8. Subject is willing to forgo cosmetic procedures 3 months prior to and for the duration of the study.

9. Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.

10. Subject is able to follow their normal skin care routines and to refrain from introducing any new skin care products during the study.

11. Subject is able to forgo changes in baseline medications and nutritional supplements during the study period.

12. If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.

13. If currently using hormonal contraception, has been using this form of contraception for at least 6 months and agrees to continue using the same contraception for the duration of the study.

14. Subjects are willing not to introduce any new soaps, cleansers, laundry detergents, lotions, creams, shampoos etc. for the duration of the study.

15. Subjects are willing to give written informed consent and are willing to follow the study procedure.

16. Subjects who have used other marketed products for hair thinning in the past.

17. Subjects who commit not to use medicated/ prescription shampoos/hair care products (containing Minoxidil / Anti-thinning agents) or any other hair growth, treatment for thin hair, or hair products other than the test treatments for the entire duration of the study.

18. Willing to use test treatments throughout the study period.

Exclusion Criteria:

1. Subjects with a history of hair thinning/hair fall due to any clinically significant self-reported problems/s like anaemia, thyroid problems, etc.

2. Subject has a history of allergy or sensitivity to the test treatment ingredients.

3. Subject has a history of any dermatological condition of the scalp other than hair loss and/or dandruff or active dermatological condition that might interfere with the clinical assessments (e.g. tattoos, eczema, psoriasis, acne, etc.).

4. Subject has used any systemic therapy with chronic antibiotic therapy, retinoids, and/or oral steroids during the 4 weeks prior to the start or anticipates having to use at any point during the study.

5. Subject has applied any topical retinoids within 2 weeks of the screening visit or anticipates having to use at any point during the study.

6. Subject is not willing to avoid unprotected sun or other UV radiation exposure during the study period.

7. Subject is currently pregnant/breastfeeding.

8. Subject has a history of prior use of hair growth treatment within 3 months.

9. Subject has a history of any prior hair growth procedures (e.g., hair transplant or laser).

10. Subject has a history of alcohol or drug addiction.

11. Subjects who have plans of shaving scalp hair during the study.

12. Subject has a past or present condition of irritated or visibly inflamed scalp or severe scalp disease.

13. Any other condition which could warrant exclusion from the study, as per the dermatologist's/investigator's discretion.

14. Pregnant or breastfeeding or planning to become pregnant during the study period.

15. History of chronic illness which may influence the cutaneous state.

16. Subjects participating in other similar nutraceuticals, food, supplemental or therapeutic trials or hair/scalp/skin care products within the last four weeks.

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata
• Dry Skin

Intervention

Other:
• Placebo
Mode of usage: Two times a day Route of administration: Oral

Dietary Supplement:
• Botanical extract of standardized biotin
Mode of usage: Two times a day Route of administration: Oral
• Botanical extract of standardised biotin with silica
Mode of usage: Two times a day Route of administration: Oral

Locations

Country	Name	City	State
India	NovoBliss Research Pvt Ltd	Gandhinagar	Gujarat

Sponsors (2)

Lead Sponsor	Collaborator
NovoBliss Research Pvt Ltd	Orgenetics, Inc.

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in hair fall	To assess the effectiveness of test treatment in terms of change in hair fall by using 60-s hair comb test	Baseline (Day 01) before dosing to Day 30, Day 60, Day 90 post-dose, between treatments, within treatment and compare with placebo arm
Primary	Change in hair thickness (Unit= µm)	To assess the effectiveness of test treatment in terms of change in hair thickness by CASALite Nova thorough Phototrichogram	From baseline (Day 01) before dosing to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo arm
Primary	Change in hair growth rate (Unit= µm)	To assess the effectiveness of test treatment in terms of change in hair growth rate by using CASALite Nova thorough Phototrichogram	From screening (Within 4 Day) to Day 01, Day 27, Day 30, Day 57, Day 60, Day 87 and Day 90 post-dose, between treatment, within treatment, and compare with placebo arm
Primary	Change in PGA score for sign of brittle nails	To assess the effectiveness of test treatment in terms of change in PGA score for sign of brittle nails by using 5-point scoring scale Where 0= None and 5= Severe	Baseline (Day 01) before dosing of test treatments to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Primary	Change in Hair Density (Unit= sqcm)	o assess the effectiveness of test treatment in terms of change in hair density by using CASALite Nova thorough phototrichogram	rom baseline (Day 01) before dosing to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo arm
Primary	Change in PGA score for sign of Nail Surface Roughness	To assess the effectiveness of test treatment in terms of change in PGA score for sign of nail surface roughness by using 3 point scoring scale Where 0= None, 3= Severe	From baseline (Day 01) before dosing of test treatments to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Primary	Change in PGA score for sign of Surface Raggedness	To assess the effectiveness of test treatment in terms of change in PGA score for sign of nail surface raggedness by using 3 point scoring scale Where 0= None, 3= Severe	From baseline (Day 01) before dosing of test treatments to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Primary	Change in PGA score for sign of Peeling	To assess the effectiveness of test treatment in terms of change in PGA score for sign of nail surface peeling by using 4 point scoring scale where 0= none, 3= severe	From baseline (Day 01) before dosing of test treatments to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in facial wrinkle	To assess the effectiveness of test treatment in terms of change in facial wrinkles by using Visioscan VC 20plus (Instrumental Evaluation)	From baseline (Day01) to Day 30, Day 60 and Day 90, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in fine lines of crow's feet area,	To assess the effectiveness of test treatment in terms of change in fine lines of crow's feet area by using Visioscan VC 20plus (Instrumental Evaluation)	from baseline (Day01) to Day 30, Day 60 and Day 90, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in skin hydration	To assess the effectiveness of test treatment in terms of change in skin hydration by using MoistureMeterEpiD (Instrumental Evaluation)	from baseline (Day01) to Day 30, Day 60 and Day 90, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in hair Strength	To assess the effectiveness of test treatment in terms of change in hair strength by using hair pull test	From baseline (Day01) before dosing to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in skin elasticity	To assess the effectiveness of test treatment in terms of change in skin elasticity by using Cutometer Dual MPA 580(Instrumental Evaluation)	From baseline (Day01) before dosing to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in PGA Score	To assess the effectiveness of test treatment in terms of change in PGA scores i.e. dryness, redness, fine lines, coarse wrinkle, laxity, roughness, and sallowness by using Griffith scale Where 0= No appearance and 9= Severe	From baseline (Day01) before dosing to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in barrier function of skin	To assess the effectiveness of test treatment in terms of change in barrier function of skin by using Tewameter TM Hex(Instrumental Evaluation)	From baseline (Day01) before dosing to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in general appearance of hair	To assess the effectiveness of test treatment in terms of change in general appearance of hair such as hair shininess, hair reflection, hair volume, hair density, hair plasticity, hair frizziness by dermatologist trained evaluator	From baseline (Day01) before dosing to Day 30, Day 60 and Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in Anagen: Telogen ratio	To assess the effectiveness of test treatment in terms of change in Anagen: Telogen ratio of hair by using hair pluck test	From baseline (Day01) to Day 90 (+2Days), between treatments, within treatment and compare with placebo treated arm
Secondary	Change in facial photographs(Left/Center/Right)	Change in facial photographs (Left/Center/Right) of the subject by using Nikol Digital Camera D3300	From baseline before usage of test treatments on Day 01, and after usage of test treatments on Day 30, Day 60, Day 90
Secondary	Treatment perception questionnaire	To assess the effectiveness of test treatment in terms of treatment perception by using 9 point hedonic scale	From before dosing of test treatments to after usage of test treatments on Day 30, Day 60, Day 90
Secondary	Change in Complete Blood Count	Safety of test treatment will be assessed in terms of difference in Complete Blood Count	From Day 01 and Day 90
Secondary	Change in silicon deposits on hair cuticle	To assess the effect of test treatments in terms of change silicon deposits on hair cuticle by using Scanning Electrone Microscope (8 subject/ test treatment)	From baseline (Day01) before dosing to Day 90 post-dose, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in Skin Texture	To assess the effectiveness of test treatment in terms of change in Skin texture by using Visioscan VC 20plus	From baseline (Day01) to Day 30, Day 60 and Day 90, between treatments, within treatment and compare with placebo treated arm
Secondary	Change in Total Serum Cholesterol	Safety of test treatment will be assessed in terms of difference in Total Serum Cholesterol level	From Day 01 and Day 90
Secondary	Change in Triglycerides	Safety of test treatment will be assessed in terms of difference in Triglycerides level	From Day 01 and Day 90
Secondary	Change in LDL level	Safety of test treatment will be assessed in terms of difference in LDL level	From Day 01 and Day 90
Secondary	Change in HDL level	Safety of test treatment will be assessed in terms of difference in HDL level	From Day 01 and Day 90
Secondary	Change in Random Glucose Level	Safety of test treatment will be assessed in terms of difference in Random Glucose Level	From Day 01 and Day 90